Insmed Incorporated reports results for the quarter ended September 30 - Earnings Summary

• Insmed Incorporated reported a quarterly adjusted loss of 46 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-1.75. The mean expectation of twenty one analysts for the quarter was for a loss of 38 cents per share. Wall Street expected results to range from -84 cents to -19 cents per share.

• Revenue rose 268.4% to $524.43 million from a year ago; analysts expected $501.35 million.

• Insmed Incorporated's reported EPS for the quarter was a loss of 46 cents​.

• The company reported a quarterly loss of $100.32 million.

• Insmed Incorporated shares had fallen by 15.0% this quarter and lost 44.3% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 38.6% in the last three months.​

• In the last 30 days, three analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 24 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Insmed Incorporated is $197.50, about 50.9% above its last closing price of $96.98

This summary was machine generated from LSEG data October 29 at 07:29 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)